Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece.
Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.
Patients with multiple myeloma (MM) have a suboptimal antibody response following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lower seroconversion rates following coronavirus disease 2019 (COVID-19) compared with healthy individuals. In this context, we evaluated the development of neutralising antibodies (NAbs) against SARS-CoV-2 in non-vaccinated patients with MM and COVID-19 compared with patients after vaccination with two doses of the BNT162b2 vaccine. Serum was collected either four weeks post confirmed diagnosis or four weeks post a second dose of BNT162b2. NAbs were measured with a Food and Drug Administration-approved enzyme-linked immunosorbent assay methodology. Thirty-five patients with COVID-19 and MM along with 35 matched patients were included. The two groups did not differ in age, sex, body mass index, prior lines of therapy, disease status, lymphocyte count, immunoglobulin levels and comorbidities. Patients with MM and COVID-19 showed a superior humoral response compared with vaccinated patients with MM. The median (interquartile range) NAb titre was 87·6% (71·6-94%) and 58·7% (21·4-91·8%) for COVID-19-positive and vaccinated patients, respectively (P = 0·01).Importantly, there was no difference in NAb production between COVID-19-positive and vaccinated patients who did not receive any treatment (median NAb 85·1% vs 91·7%, P = 0·14). In conclusion, our data indicate that vaccinated patients with MM on treatment without prior COVID-19 should be considered for booster vaccine doses.
多发性骨髓瘤（MM）患者接种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗后的抗体反应不佳，且与健康个体相比，新型冠状病毒病 2019（COVID-19）后的血清转化率较低。在这种情况下，我们评估了未接种疫苗的 MM 合并 COVID-19 患者与接种两剂 BNT162b2 疫苗的患者相比，针对 SARS-CoV-2 的中和抗体（NAb）的产生情况。血清采集于确诊后四周或第二剂 BNT162b2 后四周。NAb 通过美国食品和药物管理局批准的酶联免疫吸附测定方法进行测量。共纳入 35 例 COVID-19 合并 MM 患者和 35 例匹配患者。两组在年龄、性别、体重指数、既往治疗线数、疾病状态、淋巴细胞计数、免疫球蛋白水平和合并症方面无差异。与接种疫苗的 MM 患者相比，MM 合并 COVID-19 的患者表现出更好的体液反应。COVID-19 阳性和接种疫苗患者的 NAb 滴度中位数（四分位距）分别为 87.6%（71.6-94%）和 58.7%（21.4-91.8%）（P=0.01）。重要的是，未接受任何治疗的 COVID-19 阳性和接种疫苗患者之间的 NAb 产生没有差异（中位数 NAb 分别为 85.1%和 91.7%，P=0.14）。总之，我们的数据表明，未感染 COVID-19 且正在接受治疗的 MM 接种患者应考虑加强疫苗剂量。
